$ROIV 8-K SEC Filings

Filed On	Filing
21 Oct 2026	8-K: Regulation FD Disclosure Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)
18 Sep 2026	8-K: Submission of Matters to a Vote of Security Holders On September 16, 2026, Roivant Sciences Ltd. (the “Company”) held its 2026 Annual General Meeting of Shareholders. At that meeting, the shareholders considered and acted upon three proposals as described in more detail in the Company’s p...
08 Sep 2026	8-K: Regulation FD Disclosure Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
28 Aug 2026	8-K: Other Events
27 Aug 2026	8-K: Regulation FD Disclosure
06 Aug 2026	8-K: Results of Operations and Financial Condition
20 May 2026	8-K: Results of Operations and Financial Condition
02 Apr 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
03 Mar 2026	8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more
03 Mar 2026	8-K: Regulation FD Disclosure
06 Feb 2026	8-K: Results of Operations and Financial Condition
11 Dec 2025	8-K: Regulation FD Disclosure
10 Nov 2025	8-K: Results of Operations and Financial Condition
17 Sep 2025	8-K: Regulation FD Disclosure; Other Events
11 Sep 2025	8-K: Submission of Matters to a Vote of Security Holders
03 Sep 2025	8-K: Regulation FD Disclosure; Other Events
11 Aug 2025	8-K: Results of Operations and Financial Condition
25 Jun 2025	8-K: Other Events
29 May 2025	8-K: Results of Operations and Financial Condition
21 Apr 2025	8-K: Regulation FD Disclosure

Comments